What is the current size and annual growth rate of the prostate cancer drugs market?
The prostate cancer drugs market size has grown strongly in recent years. It will grow from $18.53 billion in 2024 to $19.77 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to aging population, increased diagnoses, drug innovation, awareness and education, reimbursement and insurance.
The prostate cancer drugs market size is expected to see strong growth in the next few years. It will grow to $25.13 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to growing incidence, emerging markets, supportive government policies, r&d investments. Major trends in the forecast period include precision medicine, immunotherapy and targeted therapies, personalized medicine, clinical trials and drug pipeline, combination therapies, biomarker-driven treatments, telemedicine and remote monitoring.
Get Your Free Sample of The Global Prostate Cancer Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2592&type=smp
Which major factors have contributed to the expansion of the prostate cancer drugs market?
The increasing men geriatric population is a major driver for the prostate cancer drugs market. Prostate cancer is one of the most common types of cancer in men aged above 60. According to ACL (Administration For Community Living), a US-based government organization, the geriatric population is expected to increase by 21.6% by 2040. Among those population, men are affected more with prostate cancer than women. For example, in January 2022, according to American Cancer Society, a US-based organization, prostate cancer develops in older men and in non-hispanicblack menand about 6 cases in 10 are diagnosed in men who are 65 or older (geriatric population). Therefore, increasing men geriatric population drives the growth of the prostate cancer market.
How is the prostate cancer drugs market segmented?
The prostate cancer drugs market covered in this report is segmented –
1) By Type: Hormone Sensitive Prostate Cancer, Hormone Refractory Prostate Cancer
2) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy
3) By End User: Hospitals, Clinics, Other End-Users
Subsegments:
1) By Hormone Sensitive Prostate Cancer: Early-Stage Prostate Cancer, Locally Advanced Prostate Cancer, Metastatic Prostate Cancer
2) By Hormone Refractory Prostate Cancer: Castration-Resistant Prostate Cancer (CRPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report
Who are the top competitors in the prostate cancer drugs market?
Major companies operating in the prostate cancer drugs market include Astellas Pharma Inc., AstraZeneca PLC, Johnson & Johnson, Sanofi S.A., Bayer AG, F. Hoffmann-La Roche AG, Abbott Laboratories, Pfizer Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Tolmar Inc., AbbVie Inc., Siemens Healthineers AG, Genomic Health Inc., OPKO Health Inc., Siemens Healthcare GmbH, MDxHealth SA, Myriad Genetics Inc., Janssen Biotech Inc., Clovis Oncology Inc., Merck Sharp & Dohme Corp., Dendreon Corporation, Ferring Pharmaceuticals Inc., GlaxoSmithKline plc, Ipsen Biopharmaceuticals Inc., Merck & Co. Inc., Eli Lilly and Company Inc., Bausch Health Companies Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novartis AG, Amgen Inc., Biogen Inc., Celgene Corporation, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Agios Pharmaceuticals Inc., Exelixis Inc.
How will evolving trends contribute to the growth of the prostate cancer drugs market?
The use of combination therapy to treat prostate cancer is an emerging trend in the market. This is mainly because, in some cases of prostate cancer, monotherapy has not been effective for the patients. In this regard, companies in the prostate cancer drugs market are investing more in combination therapy for the treatment of prostate cancer. For example, Pfizer announced the results of its Phase 3 PROSPER trial in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC), which show that the use of XTANDI (enzalutamide) in combination with androgen deprivation therapy (ADT) significantly reduced the risk of developing metastases or death by 71% compared to using ADT alone. Similarly, other combination therapies such as a combination of radiation therapy and androgen deprivation therapy for men with recurrent prostate cancer, and using chemotherapy drug docetaxel (Taxotere) along with ADT are also being used to treat prostate cancer.
What are the key regional dynamics of the prostate cancer drugs market, and which region leads in market share?
North America was the largest region in the prostate cancer drugs market in 2023. Middle East is expected to be the fastest-growing region in the prostate cancer drugs market during the forecast period. The regions covered in the prostate cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Does The Prostate Cancer Drugs Market Report 2025 Offer?
The prostate cancer drugs market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
The prostate cancer drugs refer to drugs that are used for the prevention and treatment of prostate cancer. Prostate cancer is one of the most common types of cancer caused due to uncontrollable development of cells in the prostate gland in men that produces the seminal fluid that nourishes and transports sperm. Some of the possible treatments for prostate cancer include hormonal therapy, chemotherapy, immunotherapy, and targeted therapy.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2592
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
